Oruka Therapeutics reported positive week 28 outcomes from its Phase 2a clinical trial for ORKA-001, a psoriasis drug, demonstrating deepening efficacy with 71.4% of patients achieving complete skin clearance (PASI 100) and a consistent safety profile. This data suggests strong potential for the drug, which could significantly impact the company's future valuation and market position.
Oruka Therapeutics announced compelling week 28 data for its psoriasis drug ORKA-001, showing significant improvements in efficacy metrics like PASI 100 and PASI 90, along with a favorable safety profile. This positive clinical update is a major catalyst for ORKA, as it de-risks the drug's development and strengthens its commercial prospects. The deepening efficacy over time is particularly encouraging for long-term patient outcomes and market adoption. While the stock was down slightly at publication, likely due to broader market factors or previous news (Fairmount share unload), this positive data provides a strong fundamental tailwind. The upcoming 52-week data and Phase 2b results in 2026 will be crucial for sustained momentum and further validation.